(Q44273992)

English

A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

(RS)-lenalidomide

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

Angela Dispenzieri

6

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

11

object named as

David Dingli

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Stephen J. Russell

13

object named as

Stephen Russell

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

S. Vincent Rajkumar

18

object named as

S Vincent Rajkumar

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

7

object named as

Morie A Gertz

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Suzanne R Hayman

9

object named as

Suzanne Hayman

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

12

object named as

John Lust

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

3

object named as

Shaji K Kumar

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

P Leif Bergsagel

16

object named as

P Leif Bergsagel

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

2

object named as

Craig B Reeder

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

15

object named as

Joseph R Mikhael

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Kristina M Laumann

14

object named as

Kristina M Laumann

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

5

object named as

Donna E Reece

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Phillip R Greipp

8

object named as

Phillip Greipp

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

author name string

Meaghan L Khan

1

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Marthy Q Lacy

4

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Steven Zeldenhurst

10

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

A Keith Stewart

19

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

language of work or name

0 references

publication date

23 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

156

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

326-333

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08949.X

21 January 2018

Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08949.X

21 January 2018

Recent major improvement in long-term survival of younger patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08949.X

21 January 2018

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08949.X

21 January 2018

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08949.X

21 January 2018

Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08949.X

21 January 2018

Improved survival in multiple myeloma and the impact of novel therapies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08949.X

21 January 2018

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08949.X

21 January 2018

Multiple myeloma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08949.X

21 January 2018

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08949.X

21 January 2018

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08949.X

21 January 2018

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08949.X

21 January 2018

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08949.X

21 January 2018

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08949.X

21 January 2018

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08949.X

21 January 2018

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08949.X

21 January 2018

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08949.X

21 January 2018

How I treat multiple myeloma in younger patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08949.X

21 January 2018

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08949.X

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08949.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2011.08949.X

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44273992&oldid=2109057714"